Nicoletta Luciano
Overview
Explore the profile of Nicoletta Luciano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luciano N, Barone E, Brunetta E, DIsanto A, De Santis M, Ceribelli A, et al.
Arthritis Res Ther
. 2025 Jan;
27(1):2.
PMID: 39754234
Background: There is still a significant proportion of patients with rheumatoid arthritis (RA) in whom multiple therapeutic lines are ineffective. These cases are defined by the EULAR criteria as Difficult-to-Treat...
2.
De Santis M, Tonutti A, Isailovic N, Motta F, Rivara R, Ragusa R, et al.
Front Immunol
. 2024 Dec;
15:1455134.
PMID: 39697337
Background: The phosphodiesterase 4 (PDE4) inhibitor apremilast downregulates the production of IL-23 and other pro-inflammatory cytokines involved in the pathogenesis of psoriatic arthritis (PsA). Aim: To investigate the effects of...
3.
DOnofrio B, Virelli G, Pedrollo E, Caprioli M, Riva M, Renna D, et al.
Rheumatol Adv Pract
. 2024 Sep;
8(3):rkae105.
PMID: 39263208
Objectives: Parvovirus B19 most frequently causes epidemics of erythema infectiosum in children but also affects adults often leading to rheumatologic manifestations. While the serum profile allows the diagnosis, manifestations may...
4.
Ramonda R, Lorenzin M, Chimenti M, DAngelo S, Marchesoni A, Selmi C, et al.
Front Immunol
. 2024 Jul;
15():1435599.
PMID: 39076975
Objectives: This study aims to evaluate in a real-life Italian multicenter cohort of axial spondyloarthritis (axSpA) (1) the 4-year effectiveness and safety of secukinumab, (2) the drug retention rate (DRR),...
5.
Doneddu P, Borroni R, Ceribelli A, Carta F, Sechi M, Moretti G, et al.
Muscle Nerve
. 2024 Jun;
70(3):371-378.
PMID: 38940240
Introduction/aims: Laboratory and clinical data suggest a link between neurologically mediated inflammation and psoriasis, but the risk and features of peripheral neuropathy in psoriasis or psoriatic arthritis remain unknown. The...
6.
Luciano N, Barone E, Timilsina S, Gershwin M, Selmi C
Clin Rev Allergy Immunol
. 2023 Dec;
65(3):403-419.
PMID: 38157095
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by an increased risk of cardiovascular events, due to the complex interplay between traditional and disease-related risk factors. Chronic inflammation and...
7.
Luchetti Gentiloni M, Paci V, Carletto A, Zabotti A, Ramonda R, Chimenti M, et al.
Arthritis Res Ther
. 2023 Oct;
25(1):196.
PMID: 37821952
Background: Upadacitinib (UPA) is a selective JAK inhibitor recently approved for the treatment of psoriatic arthritis (PsA). In this post-approval study, we aimed to evaluate the effectiveness and safety of...
8.
Lanzillotta M, Boffini N, Barone E, Cincinelli G, Gerardi M, Luciano N, et al.
J Rheumatol
. 2023 Aug;
PMID: 37527867
Objective: Oral Janus kinase inhibitors (JAKis) represent an effective strategy for rheumatoid arthritis (RA) treatment. A previous study supported that tofacitinib (TOF) is associated with higher incidence of cardiovascular (CV)...
9.
Luciano N, Selmi C
Rheumatology (Oxford)
. 2023 Jan;
62(8):2637-2638.
PMID: 36702466
No abstract available.
10.
Luciano N, Fusaro E, Ditto M, Ianniello A, Bellis E, Bruni C, et al.
Rheumatol Immunol Res
. 2022 Dec;
3(1):31-37.
PMID: 36467021
Objectives: The pan-European BENEFIT study of patients with stable rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA) who transitioned from reference etanercept to SB4 found no clinically meaningful changes in disease...